Table 4 Market share of prophylactic uterotonics under current and new environment (2022–2026)
Intervention | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
Current Environment (without Heat-Stable Carbetocin) | |||||
 Oxytocin | 80% | 80% | 80% | 80% | 80% |
 Misoprostol | 20% | 20% | 20% | 20% | 20% |
New Environment (with Heat-Stable Carbetocin) | |||||
 Heat-stable carbetocin | 0.2% | 2% | 6% | 13% | 19% |
 Oxytocin | 79.8% | 78% | 75% | 69% | 63% |
 Misoprostol | 20% | 20% | 19% | 18% | 18% |